I Built A Billion-Dollar Company, Lost It All... Then Built Another 5 - Robert Wessman

What does it take to build not just one billion-dollar company, but seven and start again after losing it all? In this episode, Robert Wessman shares the mindset, discipline and foresight behind building one of the world’s most ambitious biosimilars platforms.This week on Leading Beyond The Lab, Lawrence Rose sat down with Robert Wessman, Founder and Executive Chairman, with over 25 years of experience spanning global pharmaceuticals, generics, biosimilars and serial entrepreneurship.In this episode, Robert Wessman covers:(01:12) Why biologics dominate the future of pharmaceuticals and the urgent need to expand access through biosimilars, with treatment costs reaching up to $100,000 per patient annually(04:10) Building seven companies including six unicorns, and scaling a global generics business across 80+ countries with over 16,500 employees(12:32) The seven-pillar framework behind building high-performance culture, including vision setting, team alignment and execution discipline(18:14) The importance of timing in biotech, and how starting too early or too late in biosimilars can determine success or failure(38:16) Strategic foresight in action, from anticipating regulatory changes to building one of the largest biosimilars pipelines with over 30 productsThis conversation offers a clear, experience-backed perspective on scaling in life sciences, building resilient organisations and making high-impact decisions in complex markets. If you are working in biotech, pharma or leadership, this episode provides practical insights worth applying.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@life_sciencesRobert WessmanLinkedIn: https://www.linkedin.com/in/robert-wessman/Lawrence RoseLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Introduction00:46 The global cost challenge of biologics01:12 Market dynamics and future of biosimilars03:11 Origins of building multiple pharma companies04:10 Scaling Actavis into a global leader05:22 Repeatable frameworks for building companies06:53 Execution, culture and operational excellence10:01 Building Alvotech in Iceland11:10 Hiring globally and building culture12:32 The seven pillars of high-performance culture15:28 Execution and accountability at scale17:03 Scaling rapidly while maintaining culture18:14 Timing the biosimilars market19:27 Fundraising and early-stage selling22:07 Building partnerships and licensing strategy24:21 Manufacturing strategy and infrastructure25:49 Business development and commercial model27:11 Building global supply chains28:23 Transitioning leadership roles30:29 Evolution of CEO skillsets32:03 AI and the future of work in pharma34:03 Hiring for high-performance teams36:33 Managing risk and operational challenges37:07 Reducing development costs through foresight38:16 Scaling pipeline strategy40:25 Patent challenges and market barriers42:19 Anticipating market shifts in biologics44:11 Navigating setbacks and industry challenges45:26 Market dynamics and global pricing pressures47:08 Why Iceland as a strategic base50:47 Attracting global talent to Iceland53:09 Capital markets and disciplined growth54:40 Risks of overfunding55:04 Personal story and adversity58:19 Near-death cycling accident01:00:30 Recovery and resilience01:05:55 Impact on mindset and life perspective#LeadingBeyondTheLab #ARTOTalent #Biotech #Pharmaceuticals #Biosimilars #LifeSciences #Leadership Hosted on Acast. See acast.com/privacy for more information.